Stemline Therapeutics,Inc. (NASDAQ:STML) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k

7 years ago

Stemline Therapeutics,Inc. (NASDAQ:STML) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07.Submission of Matters to a Vote of Security Holders.

The 2018 annual meeting of stockholders of Stemline Therapeutics,Inc. (“Stemline”) was held on June21, 2018. The following matters were voted on by the stockholders: (i)the election of five directors; (ii)the ratification of the appointment of Ernst& Young LLP as Stemline’s independent registered public accounting firm for the year ending December31, 2018; and (iii)the approval of an amendment to Stemline’s 2016 Equity Incentive Plan to increase the number of authorized shares issuable by 2,900,000 shares.

Item 1: Election of directors:

Nominee	TotalVotesFor	TotalVotes Withheld	BrokerNon-Votes
Ivan Bergstein	19,928,914	631,444	4,882,449
Alan Forman	18,264,343	2,296,015	4,882,449
Mark Sard	20,545,384	14,974	4,882,449
Darren Cline	20,545,284	15,074	4,882,449
Daniel Hume	20,545,345	15,013	4,882,449

Item 2: Ratification of the appointment of Ernst& Young LLP as Stemline’s independent registered public accounting firm for the year ending December31, 2018:

TotalVotesFor	TotalVotesAgainst	Abstention	BrokerNon-Votes
25,430,520	7,508	4,779

Item 3: Vote to approve an amendment to Stemline’s 2016 Equity Incentive Plan to increase the number of authorized shares issuable by 2,900,000 shares:

TotalVotesFor	TotalVotesAgainst	Abstention	BrokerNon-Votes
13,039,687	7,498,535	22,136	4,882,449

About Stemline Therapeutics,Inc. (NASDAQ:STML)
Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.